Apellis Pharmaceuticals Inc (NASDAQ: APLS) kicked off on Monday, down -15.02% from the previous trading day, before settling in for the closing price of $27.3. Over the past 52 weeks, APLS has traded in a range of $16.10-$31.17.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 20.08%. While this was happening, its average annual earnings per share was recorded 116.25%. With a float of $103.88 million, this company’s outstanding shares have now reached $126.50 million.
Apellis Pharmaceuticals Inc (APLS) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.90%, while institutional ownership is 99.38%. The most recent insider transaction that took place on Jan 05 ’26, was worth 77,097. In this transaction Chief Medical Officer of this company sold 3,020 shares at a rate of $25.53, taking the stock ownership to the 91,206 shares. Before that another transaction happened on Jan 05 ’26, when Company’s Officer proposed sale 3,020 for $25.53, making the entire transaction worth $77,097.
Apellis Pharmaceuticals Inc (APLS) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.29 earnings per share (EPS), higher than consensus estimate (set at -0.41) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 116.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 61.90% during the next five years compared to 20.08% growth over the previous five years of trading.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Take a look at Apellis Pharmaceuticals Inc’s (APLS) current performance indicators. Last quarter, stock had a quick ratio of 3.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.89. Likewise, its price to free cash flow for the trailing twelve months is 37.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.30, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.06 in one year’s time.
